Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds

Phase 3positiveretatrutidePositive

AI Analysis

Summary

Eli Lilly's retatrutide, a triple agonist, demonstrated up to 25% weight loss in Phase 3 trials for obesity treatment. A study examined gray-market versions of the drug and found them to produce relatively poor weight loss outcomes.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Weight loss of up to 25% in Phase 3 trials

Importance:5/10

Sentiment:

0.60

obesityweight losstriple agonistPhase 3gray marketdrug efficacy

Related Companies

$LLY

Read the original article

Published by Endpoints News on August 20, 2026 3:12 PM

Read Original